Rodman & Renshaw Starts Rigel Pharma (RIGL) at Market Outperform, Multi-Billion Drug Potential
More News related to RIGL
- Rigel Announces Third Quarter 2009 Financial Results
- Rigel Announces Presentations at Two Investor Conferences
- Rigel to Webcast Analyst Briefing on October 20, 2009
- Rigel Pharma (RIGL) Prices 13M Shares at $7.25
- Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock
More News related to New Coverage
- Piper Jaffray Initiates Coverage on UQM Technologies (UQM) with an Overweight; Sees Significant Ramp in Sales Over Next 2-3 Yrs
- Piper Jaffray Initiates Coverage on Clinical Data (CLDA) with an Overweight
- Deutsche Bank Initiates Coverage on Wynn Macau with a Buy
- Consensus Forms That Despite Tremendous YTD Move, Ford (F) Is Still Undervalued
- Bernstein Initiates Coverage on Alexion Pharmaceuticals (ALXN) with at Market Perform
Rodman & Renshaw initiated coverage on Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) with a Market Outperform rating and $33 price target.
The firm said Rigel's R788 in an oral DMARD with multi-billion dollar potentail in rheumatoid arthritis (RA).
Rigel Pharmaceuticals, Inc., a clinical-stage drug development company, engages in the discovery and development of novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
